ArticleThoracic cancer2022

Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.

Kazumasa Akagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.